Cutaneous T-cell Lymphoma - 27 Studies Found
| Recruiting |
: FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides) : Cutaneous T-Cell Lymphoma : 2015-05-13 :
|
| Active, not recruiting |
: Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma : Cutaneous T-Cell Lymphoma (CTCL) : 2014-08-06 : Drug: SHAPE topical gel Other Name: SHP-141 |
| Completed |
: Forodesine in the Treatment of Cutaneous T-Cell Lymphoma : Cutaneous T-cell Lymphoma (CTCL), : 2007-07-12 : Drug: Forodesine 200 mg 2 x 100mg tablets once daily |
| Not yet recruiting |
: A Study to Assess the Feasibility of Romidepsin Combined With Brentuximab Vedotin in Cutaneous T-cell Lymphoma : Cutaneous T-cell Lymphoma (CTCL) : 2015-11-24 :
|
| Completed |
: Study of E7777 in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma and Cutaneous T-cell Lymphoma :
: 2016-02-04 : Drug: E7777 |
| Completed |
: HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL : Cutaneous T-Cell Lymphoma/Mycosis Fungoides : 2025-09-01 : HyBryte is synthetic hypericin formulated as a 0.25% hypericin ointment. |
| Completed |
: A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides : Cutaneous T-cell Lymphoma : 2025-09-01 : Orally every day starting at the dose of 150 mg/day flat dose.At Day 15, if the treatment is tolerated, patients will escalate the dose of |